SCHEMBL1498219

SCHEMBL1498219

C=C(C)C(=O)OC[N+](C)(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.50
THRB P10828 1/20 0.47
ALDH1A1 P00352 2/20 0.44
CHRM5 P08912 4/20 0.38
CHRM1 P11229 4/20 0.38
CHRM3 P20309 4/20 0.38
CHRM2 P08172 3/20 0.38
CHRM4 P08173 3/20 0.38
HTR1A P08908 2/20 0.38
CHRNB2 P17787 2/20 0.38
CHRNA7 P36544 2/20 0.38
CHRNA4 P43681 2/20 0.38
PGR P06401 1/20 0.38
TBXA2R P21731 1/20 0.38
CHRNB4 P30926 1/20 0.38
CHRNA3 P32297 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CHRNA10 Q9GZZ6 1/20 0.38
CHRNA9 Q9UGM1 1/20 0.38
GALR3 O60755 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL10629539 0.98 THRB (0.50) TSHRTHRBALDH1A1CHRM5CHRM1
Bromide SCHEMBL17536050 0.98 TSHR (0.48) TSHRTHRBALDH1A1CHRM5CHRM1
Iodide SCHEMBL21253234 0.98 TSHR (0.48) TSHRTHRBALDH1A1CHRM5CHRM1
SCHEMBL28044392 0.98 TSHR (0.48) TSHRTHRBALDH1A1CHRM5CHRM1
SCHEMBL1262355 0.90 TSHR (0.42) TSHRTHRBALDH1A1CHRM5CHRM1
Methacrylic Acid SCHEMBL28074139 0.90 THRB (0.44) TSHRTHRBALDH1A1CHRM5CHRM1
SCHEMBL11760936 0.85 TSHR (0.39) TSHRTHRBALDH1A1GALR3POLB
SCHEMBL4937680 0.85 TSHR (0.39) TSHRTHRBALDH1A1GALR3
SCHEMBL5145800 0.82 THRB (0.42) TSHRTHRBALDH1A1
SCHEMBL671829 0.80 THRB (0.47) TSHRTHRBALDH1A1CHRM5CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6932984-B1 Method of microencapsulation TAGRA BIOTECHNOLOGIES LTD. (IL) 2005-08-23 US claimed
US-6635277-B2 Once-a-day controlled release treatment for cardiovascular disorders; bioavailability WOCKHARDT LIMITED (IN) 2003-10-21 US claimed
US-20030003149-A1 Composition for pulsatile delivery of diltiazem and process of manufacture WOCKHARDT LIMITED (IN) 2003-01-02 US claimed
US-20260138230-A1 POLISHING COMPOSITION FOR SEMICONDUCTOR PROCESS AND SUBSTRATE POLISHING METHOD USING THE SAME SK ENPULSE CO., LTD. (KR) 2026-05-21 US disclosed
EP-4726004-A1 POLISHING COMPOSITION FOR SEMICONDUCTOR PROCESS AND SUBSTRATE POLISHING METHOD USING SAME SK enpulse Co., Ltd. (KR) 2026-04-15 EP disclosed
WO-2025014039-A1 POLISHING COMPOSITION FOR SEMICONDUCTOR PROCESS AND SUBSTRATE POLISHING METHOD USING SAME 에스케이엔펄스 주식회사 2025-01-16 WO disclosed
US-11390717-B2 Coating composition LG CHEM, LTD. (KR) 2022-07-19 US disclosed
EP-3536752-B1 COATING COMPOSITION LG CHEMICAL LTD (KR) 2021-12-29 EP disclosed
US-10767056-B2 Coating composition including a salt having a silsesquioxane anion LG CHEM, LTD. (KR) 2020-09-08 US disclosed
EP-3536751-B1 COATING COMPOSITION LG CHEMICAL LTD (KR) 2020-09-02 EP disclosed
US-20190276620-A1 COATING COMPOSITION LG CHEM, LTD. (KR) 2019-09-12 US disclosed
EP-2473095-B1 ORAL DOSAGE FORM, COMPRISING AT LEAST ONE BIOLOGICALLY ACTIVE AGENT, FORMULATION AUXILIARY SUBSTANCES AND MAGNETIZABLE PARTICLES EVONIK ROEHM GMBH (DE) 2014-11-12 EP disclosed
EP-2473095-A1 ORAL DOSAGE FORM, COMPRISING AT LEAST ONE BIOLOGICALLY ACTIVE AGENT, FORMULATION AUXILIARY SUBSTANCES AND MAGNETIZABLE PARTICLES Evonik Röhm GmbH (DE) 2012-07-11 EP disclosed
US-20120143039-A1 ORAL DOSAGE FORM, COMPRISING AT LEAST ONE BIOLOGICALLY ACTIVE AGENT, FORMULATION AUXILIARY SUBSTANCES AND MAGNETIZABLE PARTICLES EVONIK ROEHM GMBH (DE) 2012-06-07 US disclosed
WO-2011026808-A1 ORAL DOSAGE FORM, COMPRISING AT LEAST ONE BIOLOGICALLY ACTIVE AGENT, FORMULATION AUXILIARY SUBSTANCES AND MAGNETIZABLE PARTICLES EVONIK RÖHM GMBH (DE) 2011-03-10 WO disclosed
WO-2010007222-A1 METHOD FOR THE ASSISTED RECOVERY OF HYDROCARBONS USING ASSOCIATIVE POLYMERS IFP (FR) 2010-01-21 WO disclosed
US-6635277-B2 Once-a-day controlled release treatment for cardiovascular disorders; bioavailability WOCKHARDT LIMITED (IN) 2003-10-21 US disclosed
US-20030003149-A1 Composition for pulsatile delivery of diltiazem and process of manufacture WOCKHARDT LIMITED (IN) 2003-01-02 US disclosed
US-5939469-A Coating materials for ink-jet printing BASF AKTIENGESELLSCHAFT (DE) 1999-08-17 US disclosed
US-4631226-A ACRYLATE AND OXIRANYL ACRYLATE COPOLYMERS, POLYAMINES FOR SHRINKAGE RESISTANCE IN WOOL, COTTON COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATION (AU) 1986-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260138230-A1 POLISHING COMPOSITION FOR SEMICONDUCTOR PROCESS AND SUBSTRATE POLISHING METHOD USING THE SAME PRKG1, PRKG2, DNMT3A TSHR 2869/4885THRB 3811/4885ALDH1A1 1645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.